0.9500
0.0000
(0.00%)
At close: April 8 at 4:36:49 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,292
10,292
20,300
57,866
17,741
Operating Income
-10,292
-10,292
-20,300
-57,866
-17,741
Net Non Operating Interest Income Expense
635
635
207
9
9
Pretax Income
-9,657
-9,657
-20,093
-57,857
-17,732
Tax Provision
-1,249
-1,249
-2,448
-9,194
-3,816
Net Income Common Stockholders
-8,408
-8,408
-17,645
-48,663
-13,916
Diluted NI Available to Com Stockholders
-8,408
-8,408
-17,645
-48,663
-13,916
Basic EPS
-0.05
-0.04
-0.09
-0.24
-0.09
Diluted EPS
-0.05
-0.04
-0.09
-0.24
-0.09
Basic Average Shares
201,360
201,148.3250
201,426.9410
200,424.2170
147,103.5940
Diluted Average Shares
201,360
201,148.3250
201,426.9410
200,424.2170
147,103.5940
Total Operating Income as Reported
-10,292
-10,292
-20,300
-57,866
-17,741
Rent Expense Supplemental
168
168
168
70
--
Total Expenses
10,292
10,292
20,300
57,866
17,741
Net Income from Continuing & Discontinued Operation
-8,408
-8,408
-17,645
-48,663
-13,916
Normalized Income
-8,408
-8,408
-17,645
-48,663
-13,916
Interest Income
635
635
207
11
19
Interest Expense
--
--
--
2
10
Net Interest Income
635
635
207
9
9
EBIT
-10,292
-10,292
-20,300
-57,855
-17,722
EBITDA
-10,208
-10,208
-20,198
-57,660
-17,462
Reconciled Depreciation
84
84
102
195
260
Net Income from Continuing Operation Net Minority Interest
-8,408
-8,408
-17,645
-48,663
-13,916
Normalized EBITDA
-10,208
-10,208
-20,198
-57,660
-17,462
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0002
0.0002
12/31/2020 - 10/26/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
POLB.L Poolbeg Pharma PLC
2.7000
0.00%
2GH.BE Merus NV
36.80
+6.36%
RNUGF ReNeuron Group plc
0.0011
0.00%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
RPD.MU Royalty Pharma plc
28.20
-3.09%
GYX.F Futura Medical plc
0.0910
+12.35%
2HA.F Spero Therapeutics, Inc.
0.4965
-7.20%
HQ1.MU Oruka Therapeutics Inc. R
6.40
0.00%
7PO.F Poxel S.A.
0.5300
0.00%
P0F.F Egetis Therapeutics AB (publ)
0.3270
+2.35%